Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock Rated “Moderate Buy” by Sell-Side Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $20.11.

Several brokerages recently issued reports on PHAT. Barclays decreased their price target on shares of Phathom Pharmaceuticals from $18.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Needham & Company LLC cut their price objective on shares of Phathom Pharmaceuticals from $28.00 to $22.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Craig Hallum reiterated a “buy” rating and set a $15.00 target price on shares of Phathom Pharmaceuticals in a report on Wednesday, October 21st. HC Wainwright reissued a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Friday. Finally, Citigroup restated a “buy” rating on shares of Phathom Pharmaceuticals in a research note on Friday.

Phathom Pharmaceuticals Trading Down 7.7%

PHAT opened at $5.74 on Friday. The stock has a fifty day simple moving average of $7.64 and a two-hundred day simple moving average of $10.47. The company has a market cap of $464.37 million, a price-to-earnings ratio of -5.57 and a beta of 0.50. Phathom Pharmaceuticals has a 12-month low of $5.01 and a 12-month high of $18.31.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its position in shares of Phathom Pharmaceuticals by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 124,018 shares of the company’s stock worth $1,378,000 after buying an additional 1,051 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Phathom Pharmaceuticals by 16.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,761 shares of the company’s stock valued at $109,000 after buying an additional 2,068 shares in the last quarter. Kera Capital Partners Inc. grew its holdings in Phathom Pharmaceuticals by 10.6% during the 1st quarter. Kera Capital Partners Inc. now owns 26,826 shares of the company’s stock valued at $298,000 after buying an additional 2,571 shares in the last quarter. Summit Securities Group LLC purchased a new position in Phathom Pharmaceuticals during the 1st quarter valued at approximately $34,000. Finally, State of Alaska Department of Revenue bought a new stake in Phathom Pharmaceuticals in the 3rd quarter worth approximately $25,000. 99.01% of the stock is owned by institutional investors.

More Phathom Pharmaceuticals News

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Q3 net revenue rose 71% year over year to $84.7 million, driven by continued demand for VOQUEZNA. The company also reported more than 2 million total VOQUEZNA prescriptions filled through October 16, 2026. Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Management reaffirmed full-year 2026 revenue guidance of $310 million to $325 million, signaling confidence in the product’s commercial trajectory. Phathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook
• Positive Sentiment: The planned $0 co-pay program through BlinkRx could improve patient access and support prescription volume, although its effect on net pricing and margins will be watched. Phathom Reiterates 2026 Revenue Guidance While Rolling Out $0 Co-Pay
• Neutral Sentiment: Phathom reported quarterly earnings of $0.04 per share. Results compared favorably with the year-earlier loss, but analyst assessments were mixed: one report characterized EPS as below its $0.07 consensus estimate, while another cited a consensus loss of $0.11. Phathom Q3 Earnings and Revenue Estimates
• Negative Sentiment: Revenue of $84.7 million was slightly below the approximately $84.8 million analyst estimate, while maintaining rather than raising guidance may have disappointed investors seeking further upside. Phathom Pharmaceuticals Reports Third-Quarter Results

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc (NASDAQ: PHAT) is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s principal product is Voquezna (vonoprazan), a potassium-competitive acid blocker designed to suppress stomach acid through a mechanism distinct from traditional proton pump inhibitors.

In the United States, Voquezna is approved for the treatment of Helicobacter pylori infection in combination with antibiotics and for certain forms of gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD.